会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE - IV INHIBITOR
    • 包含DIPEPTIDYPEPTIDASE-IV抑制剂的组合
    • WO0152825A2
    • 2001-07-26
    • PCT/EP0100590
    • 2001-01-19
    • NOVARTIS AGNOVARTIS ERFIND VERWALT GMBHBALKAN BOERKHUGHES THOMAS EDWARDHOLMES DAVID GRENVILLEVILLHAUER EDWIN BERNARD
    • BALKAN BOERKHUGHES THOMAS EDWARDHOLMES DAVID GRENVILLEVILLHAUER EDWIN BERNARD
    • A61K31/00A61K31/155A61K31/198A61K31/40A61K31/4025A61K31/427A61K31/44A61K31/4439A61K31/4453A61K31/505A61K31/7036A61K45/06A61P3/00A61P3/04A61P3/10A61P19/02A61P19/10A61P29/00A61P43/00
    • A61K45/06A61K31/00A61K31/4025A61K31/44A61K31/505A61K2300/00
    • The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, alpha -glucosidase inhibitors, inhibitors of gastric emptying, insulin, and alpha 2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
    • 本发明涉及包含DPP-IV抑制剂和至少一种另外的抗糖尿病化合物的组合,其优选选自胰岛素信号通路调节剂,如蛋白酪氨酸磷酸酶(PTPases)的抑制剂,非小分子模拟化合物和 谷氨酰胺 - 果糖-6-磷酸酰胺转移酶(GFAT)的抑制剂,影响失调的肝脏葡萄糖产生的化合物,如葡萄糖-6-磷酸酶(G6Pase)的抑制剂,果糖-1,6-二磷酸酶抑制剂(F-1,6- BPA),糖原磷酸化酶(GP)的抑制剂,胰高血糖素受体拮抗剂和磷酸烯醇丙酮酸羧激酶(PEPCK),丙酮酸脱氢酶激酶(PDHK)抑制剂,胰岛素敏感性增强剂,胰岛素分泌增强剂,α-葡糖苷酶抑制剂,胃排空抑制剂,胰岛素 和α2-肾上腺素能拮抗剂,用于同时,分开或顺序用于预防,延缓进展或治疗 由二肽基肽酶IV(DPP-IV)介导的病症,特别是糖尿病,尤其是2型糖尿病,葡萄糖耐量降低的病症(IGT),空腹血浆葡萄糖受损的病症,代谢性酸中毒,酮症,关节炎,肥胖症和 骨质疏松症; 以及使用这种组合来进行哺乳动物的美容治疗,以实现美容上有益​​的体重减轻。